Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Eli Lilly, the pharmaceutical company developing retatrutide, has progressed the compound into Phase 3 clinical trials, which are evaluating its efficacy and safety in larger populations across multiple indications, including obesity and type 2 diabetes
Compared to metformin and other diabetes medications, the reduction ranged from 38-55% and even compared to earlier generation GLP-1RAs (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide), semaglutide showed a 34-38% reduction
2020;23(Suppl 1):S116
Get a personalized read on your labs and symptoms in under 5 minutes
However, enhancing the endogenous secretion of GLP-1 through dietary, microbial, or pharmacological stimuli represents a promising complementary strategy
Rubbo H, Trostchansky A, ODonnell VB
